Quantcast

Latest Surrogate endpoint Stories

2014-03-18 23:26:23

Launch of ADDPLAN® 6.1 to Expedite and Improve Decision-Making in Clinical Trials Reston, Virginia (PRWEB) March 18, 2014 Aptiv Solutions, a global biopharmaceutical and medical device development services company leading the design and implementation of innovative approaches that improve data quality, efficiency, and productivity of product development, today announced the release of ADDPLAN® 6.1, the first statistical software to enable the use of surrogate endpoints to...

2013-01-10 14:03:20

Spin and bias exist in a high proportion of published studies of the outcomes and adverse side-effects of phase III clinical trials of breast cancer treatments, according to new research published in the cancer journal Annals of Oncology today (Thursday). In the first study to investigate how accurately outcomes and side-effects are reported in breast cancer trials, researchers at the Princess Margaret Cancer Centre and University of Toronto (Toronto, Canada) found that in a third of all...

2010-06-21 14:00:00

SILVER SPRING, Md., June 21 /PRNewswire-USNewswire/ -- Pfizer Inc. today announced the voluntary withdrawal from the U.S. market of the drug Mylotarg (gemtuzumab ozogamicin) for patients with acute myeloid leukemia (AML), a bone marrow cancer. The company took the action at the request of the U.S. Food and Drug Administration after results from a recent clinical trial raised new concerns about the product's safety and the drug failed to demonstrate clinical benefit to patients enrolled in...

96b178e25092e359d4013e63573345e11
2009-10-27 06:15:00

The FDA needs to be more effective in determining a drug's efficiency after being approved, according to a report issued on Monday by the Government Accountability Office. The GAO said that the Food and Drug Administration is quick to approve drugs for the market, but fails to follow up on how well the drug is performing among patients. The GAO classified the FDA's process as "accelerated approval" based solely on preliminary reports rather than ensuring that the drug is working for patients...

2009-01-12 14:00:00

Company Expects to Deliver Multiple Clinical Milestones throughout the Year; Amigal to Initiate Phase 3 Global Development in Second Quarter; Continued Strong Financial Position CRANBURY, N.J., Jan. 12 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced positive progress in its three lead clinical programs for lysosomal storage disorders and presented a corporate outlook consisting of multiple clinical milestones and financial guidance for 2009 at the 27th Annual...

2008-09-17 15:00:11

MONTVALE, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. today announced that a Letter to Stockholders is now posted to the Company's Web site http://www.synvista.com/. The text is as follows: To Our Stockholders: The team at Synvista Therapeutics has made tremendous progress in our efforts to deliver on the promise of personalized medicine, and to redefine the treatment of cardiovascular disease in diabetics as well as the treatment of other diseases in the...

2005-11-17 14:24:35

LONDON (Reuters) - Cholesterol-lowering drugs may help to delay the progression of Alzheimer's disease, the leading cause of dementia in the elderly, French scientists said on Thursday. In a three-year study involving 342 Alzheimer's patients, they found that the illness did not develop as quickly in sufferers with high cholesterol levels who were given statins as in patients not taking the drugs. Professor Florence Pasquier, of the University Hospital in Lille, France, said the...

2005-11-17 01:40:00

LONDON -- Cholesterol-lowering drugs may help to delay the progression of Alzheimer's disease, the leading cause of dementia in the elderly, French scientists said on Thursday. In a three-year study involving 342 Alzheimer's patients, they found that the illness did not develop as quickly in sufferers with high cholesterol levels who were given statins as in patients not taking the drugs. Professor Florence Pasquier, of the University Hospital in Lille, France, said the drugs "may slow...


Word of the Day
ween
  • To think; to imagine; to fancy.
  • To be of opinion; have the notion; think; imagine; suppose.
The word 'ween' comes from Middle English wene, from Old English wēn, wēna ("hope, weening, expectation"), from Proto-Germanic *wēniz, *wēnōn (“hope, expectation”), from Proto-Indo-European *wen- (“to strive, love, want, reach, win”).
Related